Literature DB >> 21275498

5-Fluorouracil-induced Tako-Tsubo-like syndrome.

Cécile Basselin1, Thierry Fontanges, Jacques Descotes, Philippe Chevalier, Bernard Bui-Xuan, Gwennaelle Feinard, Quadiri Timour.   

Abstract

Tako-Tsubo cardiomyopathy (also known as apical ballooning syndrome) is a relatively new clinical entity characterized by reversible left ventricular dysfunction. Its clinical presentation and electrocardiographic findings are similar to acute myocardial infarction but without significant coronary artery disease. Cardiotoxicity is a major complication of various anticancer drugs; however, only a few cases of Tako-Tsubo cardiomyopathy associated with anticancer drugs, including 5-fluorouracil, have been reported. We describe a 48-year-old man who developed acute coronary syndrome, thought to be similar to Tako-Tsubo syndrome, after receiving a chemotherapy regimen consisting of 5-fluorouracil, oxaliplatin, and calcium folinate (FOLFOX protocol) for colic adenocarcinoma. Approximately 24 hours after receiving his first cycle of chemotherapy, the patient, who did not have a history of cardiovascular disease, developed chest pain, with abnormal electrocardiographic results and a mildly increased troponin T level. Coronary angiography did not show any significant coronary lesions. Echocardiography revealed marked left ventricular dysfunction (left ventricular ejection fraction [LVEF] 15%) with severe hypokinesia in all apical and median segments. The patient was stabilized with the introduction of an intraaortic balloon pump and pressor therapy. One month later, myocardial magnetic resonance imaging confirmed total recovery of left ventricular systolic function. Thus, the second chemotherapy cycle was administered at half the dose-intensity, along with ramipril and diltiazem. The chemotherapy regimen was well tolerated. Two weeks later, at the end of the third chemotherapy cycle, administered using the full-dose regimen, the patient experienced cardiac arrest, necessitating cardiopulmonary resuscitation. After transfer to the cardiology intensive care unit, acute heart failure recurred (LVEF 35%). Normal recovery of left ventricular function occurred a few days later. Chemotherapy was discontinued, and treatment with bisoprolol was started. Four months later, the patient remained completely asymptomatic of any cardiac manifestations. Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 8) between the patient's development of acute coronary Tako-Tsubo-like syndrome and 5-fluorouracil. Clinicians should be aware of this potential adverse effect when monitoring patients receiving chemotherapy with 5-fluorouracil.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21275498     DOI: 10.1592/phco.31.2.226

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  25 in total

Review 1.  Ischemic Heart Disease: Special Considerations in Cardio-Oncology.

Authors:  Dana Elena Giza; Fernando Boccalandro; Juan Lopez-Mattei; Gloria Iliescu; Kaveh Karimzad; Peter Kim; Cezar Iliescu
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-05

Review 2.  Cardiovascular complications of metastatic colorectal cancer treatment.

Authors:  Kalliopi Keramida; Georgios Charalampopoulos; Dimitrios Filippiadis; Elias Tsougos; Dimitrios Farmakis
Journal:  J Gastrointest Oncol       Date:  2019-08

3.  Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?

Authors:  Kien Hoe Ng; Claire Dearden; Pascale Gruber
Journal:  BMJ Case Rep       Date:  2015-03-02

Review 4.  Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.

Authors:  Dana Elena Giza; Kostas Marmagkiolis; Elie Mouhayar; Jean-Bernard Durand; Cezar Iliescu
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

Review 5.  New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.

Authors:  Oreste Lanza; Armando Ferrera; Simone Reale; Giorgio Solfanelli; Mattia Petrungaro; Giacomo Tini Melato; Massimo Volpe; Allegra Battistoni
Journal:  Med Sci (Basel)       Date:  2022-05-25

6.  Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study.

Authors:  Merete Vaage-Nilsen; Dorte L Nielsen; Anne Dyhl-Polk; Morten Schou; Kirsten K Vistisen; Anne-Sophie Sillesen; Eva Serup-Hansen; Jens Faber; Tobias W Klausen; Stig E Bojesen
Journal:  Oncologist       Date:  2020-10-07

7.  Malignancy predicts outcome of Takotsubo syndrome: a systematic review and meta-analysis.

Authors:  Shaohua Guo; Bingxin Xie; Gary Tse; Leonardo Roever; Yunlong Xia; Guangping Li; Yaogang Wang; Tong Liu
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214

8.  Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab.

Authors:  Toshihiko Matsumoto; Takashi Oda; Yu Yoshida; Shogo Kimura; Hitomi Himei; Takao Tsuduki; Shinjiro Takagi; Masahiro Takatani; Hirofumi Morishita
Journal:  Int Cancer Conf J       Date:  2019-12-06

Review 9.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

10.  What the Cardiologist Needs to Consider in the Management of Oncologic Patients with STEMI-Like Syndrome: A Case Report and Literature Review.

Authors:  Aneta Aleksova; Giulia Gagno; Alessandro Pierri; Carla Todaro; Alessandra Lucia Fluca; Valentina Orlando; Alessandra Guglielmi; Antonio Paolo Beltrami; Gianfranco Sinagra
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.